{"groups":[{"description":"Abiraterone acetate plus prednisone/prednisolone administered as four 250 mg tablets of abiraterone acetate once daily plus 5 mg prednisone/5 mg prednisolone twice daily until disease progression.","id":"FG000","title":"Abiraterone Acetate"},{"description":"Placebo plus prednisone/prednisolone administered as four placebo tablets once daily plus 5 mg prednisone/5 mg prednisolone tablet twice daily until disease progression.","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"655"},{"groupId":"FG001","numSubjects":"335"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"797"},{"groupId":"FG001","numSubjects":"398"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"116"},{"groupId":"FG001","numSubjects":"56"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"681"},{"groupId":"FG001","numSubjects":"342"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}